Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
Reverse conservation analysis reveals the specificity determining residues of cytochrome P450 family 2 (CYP 2).

Evolutionary bioinformatics online

Lee TS.
PMID: 19204803
Evol Bioinform Online. 2008 Feb 09;4:7-16. doi: 10.4137/ebo.s291.

The concept of conservation of amino acids is widely used to identify important alignment positions of orthologs. The assumption is that important amino acid residues will be conserved in the protein family during the evolutionary process. For paralog alignment,...

Cite
Lee TS. Reverse conservation analysis reveals the specificity determining residues of cytochrome P450 family 2 (CYP 2). Evol Bioinform Online. 2008;4:7-16doi: 10.4137/ebo.s291.
Lee, T. S. (2008). Reverse conservation analysis reveals the specificity determining residues of cytochrome P450 family 2 (CYP 2). Evolutionary bioinformatics online, 47-16. https://doi.org/10.4137/ebo.s291
Lee, Tai-Sung. "Reverse conservation analysis reveals the specificity determining residues of cytochrome P450 family 2 (CYP 2)." Evolutionary bioinformatics online vol. 4 (2008): 7-16. doi: https://doi.org/10.4137/ebo.s291
Lee TS. Reverse conservation analysis reveals the specificity determining residues of cytochrome P450 family 2 (CYP 2). Evol Bioinform Online. 2008 Feb 09;4:7-16. doi: 10.4137/ebo.s291. PMID: 19204803; PMCID: PMC2614186.
Copy Download .nbib Format: NLM
Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma.

Molecular oncology

Gallon J, Coto-Llerena M, Ercan C, Bianco G, Paradiso V, Nuciforo S, Taha-Melitz S, Meier MA, Boldanova T, Pérez-Del-Pulgar S, Rodríguez-Tajes S, von Flüe M, Soysal SD, Kollmar O, Llovet JM, Villanueva A, Terracciano LM, Heim MH, Ng CKY, Piscuoglio S.
PMID: 34863035
Mol Oncol. 2021 Dec 04; doi: 10.1002/1878-0261.13154. Epub 2021 Dec 04.

Hepatocellular carcinomas (HCCs) usually arise from chronic liver disease (CLD). Precancerous cells in chronically inflamed environments may be 'epigenetically primed', sensitising them to oncogenic transformation. We investigated whether epigenetic priming in CLD may affect HCC outcomes by influencing the...

Cite
Gallon J, Coto-Llerena M, Ercan C, et al. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Mol Oncol. 2021;doi: 10.1002/1878-0261.13154.
Gallon, J., Coto-Llerena, M., Ercan, C., Bianco, G., Paradiso, V., Nuciforo, S., Taha-Melitz, S., Meier, M. A., Boldanova, T., Pérez-Del-Pulgar, S., Rodríguez-Tajes, S., von Flüe, M., Soysal, S. D., Kollmar, O., Llovet, J. M., Villanueva, A., Terracciano, L. M., Heim, M. H., Ng, C. K. Y., & Piscuoglio, S. (2021). Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Molecular oncology, . https://doi.org/10.1002/1878-0261.13154
Gallon, John, et al. "Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma." Molecular oncology vol. (2021). doi: https://doi.org/10.1002/1878-0261.13154
Gallon J, Coto-Llerena M, Ercan C, Bianco G, Paradiso V, Nuciforo S, Taha-Melitz S, Meier MA, Boldanova T, Pérez-Del-Pulgar S, Rodríguez-Tajes S, von Flüe M, Soysal SD, Kollmar O, Llovet JM, Villanueva A, Terracciano LM, Heim MH, Ng CKY, Piscuoglio S. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Mol Oncol. 2021 Dec 04; doi: 10.1002/1878-0261.13154. Epub 2021 Dec 04. PMID: 34863035.
Copy Download .nbib Format: NLM
ZnT8 Deficiency Protects From APAP-Induced Acute Liver Injury by Reducing Oxidative Stress Through Upregulating Hepatic Zinc and Metallothioneins.

Frontiers in pharmacology

Su W, Feng M, Liu Y, Cao R, Liu Y, Tang J, Pan K, Lan R, Mao Z.
PMID: 34413780
Front Pharmacol. 2021 Aug 03;12:721471. doi: 10.3389/fphar.2021.721471. eCollection 2021.

Zinc transporter 8 (ZnT8) is an important zinc transporter highly expressed in pancreatic islets. Deficiency of ZnT8 leads to a marked decrease in islet zinc, which is thought to prevent liver diseases associated with oxidative stress. Herein, we aimed...

Cite
Su W, Feng M, Liu Y, et al. ZnT8 Deficiency Protects From APAP-Induced Acute Liver Injury by Reducing Oxidative Stress Through Upregulating Hepatic Zinc and Metallothioneins. Front Pharmacol. 2021;12:721471doi: 10.3389/fphar.2021.721471.
Su, W., Feng, M., Liu, Y., Cao, R., Liu, Y., Tang, J., Pan, K., Lan, R., & Mao, Z. (2021). ZnT8 Deficiency Protects From APAP-Induced Acute Liver Injury by Reducing Oxidative Stress Through Upregulating Hepatic Zinc and Metallothioneins. Frontiers in pharmacology, 12721471. https://doi.org/10.3389/fphar.2021.721471
Su, Wen, et al. "ZnT8 Deficiency Protects From APAP-Induced Acute Liver Injury by Reducing Oxidative Stress Through Upregulating Hepatic Zinc and Metallothioneins." Frontiers in pharmacology vol. 12 (2021): 721471. doi: https://doi.org/10.3389/fphar.2021.721471
Su W, Feng M, Liu Y, Cao R, Liu Y, Tang J, Pan K, Lan R, Mao Z. ZnT8 Deficiency Protects From APAP-Induced Acute Liver Injury by Reducing Oxidative Stress Through Upregulating Hepatic Zinc and Metallothioneins. Front Pharmacol. 2021 Aug 03;12:721471. doi: 10.3389/fphar.2021.721471. eCollection 2021. PMID: 34413780; PMCID: PMC8369884.
Copy Download .nbib Format: NLM
[No title available]

Biomedical reports

Chanhom N, Udomsinprasert W, Chaikledkaew U, Mahasirimongkol S, Wattanapokayakit S, Jittikoon J.
PMID: 32190303
Biomed Rep. 2020 Apr;12(4):153-162. doi: 10.3892/br.2020.1275. Epub 2020 Feb 10.

Antituberculosis (anti-TB) drugs are the most common cause of drug-induced liver injury (DILI). There are numerous studies revealing the associations between the polymorphisms of pharmacogenes and the risk of anti-TB DILI (ATDILI). In the present study, relevant studies regarding...

Cite
Chanhom N, Udomsinprasert W, Chaikledkaew U, et al. . Biomed Rep. 2020;12(4):153-162doi: 10.3892/br.2020.1275.
Chanhom, N., Udomsinprasert, W., Chaikledkaew, U., Mahasirimongkol, S., Wattanapokayakit, S., & Jittikoon, J. (2020). . Biomedical reports, 12(4), 153-162. https://doi.org/10.3892/br.2020.1275
Chanhom, Noppadol, et al. "." Biomedical reports vol. 12,4 (2020): 153-162. doi: https://doi.org/10.3892/br.2020.1275
Chanhom N, Udomsinprasert W, Chaikledkaew U, Mahasirimongkol S, Wattanapokayakit S, Jittikoon J. . Biomed Rep. 2020 Apr;12(4):153-162. doi: 10.3892/br.2020.1275. Epub 2020 Feb 10. PMID: 32190303; PMCID: PMC7054707.
Copy Download .nbib Format: NLM
Liver-Metabolizing Genes and Their Relationship to the Performance of Elite Spanish Male Endurance Athletes; a Prospective Transversal Study.

Sports medicine - open

Varillas Delgado D, Tellería Orriols JJ, Martín Saborido C.
PMID: 31820125
Sports Med Open. 2019 Dec 09;5(1):50. doi: 10.1186/s40798-019-0227-7.

BACKGROUND: The genetic profile that is needed to define an endurance athlete has been studied during recent years. The main objective of this work is to approach for the first time the study of genetic variants in liver-metabolizing genes...

Cite
Varillas Delgado D, Tellería Orriols JJ, Martín Saborido C. Liver-Metabolizing Genes and Their Relationship to the Performance of Elite Spanish Male Endurance Athletes; a Prospective Transversal Study. Sports Med Open. 2019;5(1):50doi: 10.1186/s40798-019-0227-7.
Varillas Delgado, D., Tellería Orriols, J. J., & Martín Saborido, C. (2019). Liver-Metabolizing Genes and Their Relationship to the Performance of Elite Spanish Male Endurance Athletes; a Prospective Transversal Study. Sports medicine - open, 5(1), 50. https://doi.org/10.1186/s40798-019-0227-7
Varillas Delgado, David, et al. "Liver-Metabolizing Genes and Their Relationship to the Performance of Elite Spanish Male Endurance Athletes; a Prospective Transversal Study." Sports medicine - open vol. 5,1 (2019): 50. doi: https://doi.org/10.1186/s40798-019-0227-7
Varillas Delgado D, Tellería Orriols JJ, Martín Saborido C. Liver-Metabolizing Genes and Their Relationship to the Performance of Elite Spanish Male Endurance Athletes; a Prospective Transversal Study. Sports Med Open. 2019 Dec 09;5(1):50. doi: 10.1186/s40798-019-0227-7. PMID: 31820125; PMCID: PMC6901632.
Copy Download .nbib Format: NLM
Validation of an Extensive CYP2D6 Assay Panel Based on Invader and TaqMan Copy Number Assays.

The journal of applied laboratory medicine

Leung EKY, Agolini E, Pei X, Melis R, McMillin GA, Friedman PN, Peterson P, Danahey K, O'Donnell PH, Yeo KJ.
PMID: 33379799
J Appl Lab Med. 2017 Mar 01;1(5):471-482. doi: 10.1373/jalm.2016.021923.

BACKGROUND: CYP2D6 is involved in the oxidative metabolism of approximately 20% of all clinically used medications. Genotyping cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6), is a challenge because of the high complexity of the locus.METHODS: Twenty-nine CYP2D6...

Cite
Leung EKY, Agolini E, Pei X, et al. Validation of an Extensive CYP2D6 Assay Panel Based on Invader and TaqMan Copy Number Assays. J Appl Lab Med. 2017;1(5):471-482doi: 10.1373/jalm.2016.021923.
Leung, E. K. Y., Agolini, E., Pei, X., Melis, R., McMillin, G. A., Friedman, P. N., Peterson, P., Danahey, K., O'Donnell, P. H., & Yeo, K. J. (2017). Validation of an Extensive CYP2D6 Assay Panel Based on Invader and TaqMan Copy Number Assays. The journal of applied laboratory medicine, 1(5), 471-482. https://doi.org/10.1373/jalm.2016.021923
Leung, Edward Ki Yun, et al. "Validation of an Extensive CYP2D6 Assay Panel Based on Invader and TaqMan Copy Number Assays." The journal of applied laboratory medicine vol. 1,5 (2017): 471-482. doi: https://doi.org/10.1373/jalm.2016.021923
Leung EKY, Agolini E, Pei X, Melis R, McMillin GA, Friedman PN, Peterson P, Danahey K, O'Donnell PH, Yeo KJ. Validation of an Extensive CYP2D6 Assay Panel Based on Invader and TaqMan Copy Number Assays. J Appl Lab Med. 2017 Mar 01;1(5):471-482. doi: 10.1373/jalm.2016.021923. PMID: 33379799.
Copy Download .nbib Format: NLM
Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma.

Molecular oncology

Gallon J, Coto-Llerena M, Ercan C, Bianco G, Paradiso V, Nuciforo S, Taha-Melitz S, Meier MA, Boldanova T, Pérez-Del-Pulgar S, Rodríguez-Tajes S, von Flüe M, Soysal SD, Kollmar O, Llovet JM, Villanueva A, Terracciano LM, Heim MH, Ng CKY, Piscuoglio S.
PMID: 34863035
Mol Oncol. 2021 Dec 04; doi: 10.1002/1878-0261.13154. Epub 2021 Dec 04.

Hepatocellular carcinomas (HCCs) usually arise from chronic liver disease (CLD). Pre-cancerous cells in chronically inflamed environments may be 'epigenetically primed', sensitising them to oncogenic transformation. We investigated whether epigenetic priming in CLD may affect HCC outcomes by influencing the...

Cite
Gallon J, Coto-Llerena M, Ercan C, et al. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Mol Oncol. 2021;doi: 10.1002/1878-0261.13154.
Gallon, J., Coto-Llerena, M., Ercan, C., Bianco, G., Paradiso, V., Nuciforo, S., Taha-Melitz, S., Meier, M. A., Boldanova, T., Pérez-Del-Pulgar, S., Rodríguez-Tajes, S., von Flüe, M., Soysal, S. D., Kollmar, O., Llovet, J. M., Villanueva, A., Terracciano, L. M., Heim, M. H., Ng, C. K. Y., & Piscuoglio, S. (2021). Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Molecular oncology, . https://doi.org/10.1002/1878-0261.13154
Gallon, John, et al. "Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma." Molecular oncology vol. (2021). doi: https://doi.org/10.1002/1878-0261.13154
Gallon J, Coto-Llerena M, Ercan C, Bianco G, Paradiso V, Nuciforo S, Taha-Melitz S, Meier MA, Boldanova T, Pérez-Del-Pulgar S, Rodríguez-Tajes S, von Flüe M, Soysal SD, Kollmar O, Llovet JM, Villanueva A, Terracciano LM, Heim MH, Ng CKY, Piscuoglio S. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Mol Oncol. 2021 Dec 04; doi: 10.1002/1878-0261.13154. Epub 2021 Dec 04. PMID: 34863035.
Copy Download .nbib Format: NLM
Associations of CYP2B6 genetic polymorphisms with Hirschsprung's disease in a southern Chinese population.

Journal of clinical laboratory analysis

Liu Y, Lan C, Li B, Wang N, Zuo X, Huang L, Wu Y, Zhu Y.
PMID: 34752660
J Clin Lab Anal. 2021 Dec;35(12):e24074. doi: 10.1002/jcla.24074. Epub 2021 Nov 09.

BACKGROUND: Hirschsprung's disease (HSCR) is an enteric nervous system birth defect partially caused by a genetic disorder. Single-nucleotide polymorphisms (SNPs) of the cytochrome P450 family 2 subfamily B member 6 (CYP2B6) gene are reported to be associated with HSCR.METHODS:...

Cite
Liu Y, Lan C, Li B, et al. Associations of CYP2B6 genetic polymorphisms with Hirschsprung's disease in a southern Chinese population. J Clin Lab Anal. 2021;35(12):e24074doi: 10.1002/jcla.24074.
Liu, Y., Lan, C., Li, B., Wang, N., Zuo, X., Huang, L., Wu, Y., & Zhu, Y. (2021). Associations of CYP2B6 genetic polymorphisms with Hirschsprung's disease in a southern Chinese population. Journal of clinical laboratory analysis, 35(12), e24074. https://doi.org/10.1002/jcla.24074
Liu, Yanqing, et al. "Associations of CYP2B6 genetic polymorphisms with Hirschsprung's disease in a southern Chinese population." Journal of clinical laboratory analysis vol. 35,12 (2021): e24074. doi: https://doi.org/10.1002/jcla.24074
Liu Y, Lan C, Li B, Wang N, Zuo X, Huang L, Wu Y, Zhu Y. Associations of CYP2B6 genetic polymorphisms with Hirschsprung's disease in a southern Chinese population. J Clin Lab Anal. 2021 Dec;35(12):e24074. doi: 10.1002/jcla.24074. Epub 2021 Nov 09. PMID: 34752660; PMCID: PMC8649360.
Copy Download .nbib Format: NLM
Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma.

Molecular oncology

Gallon J, Coto-Llerena M, Ercan C, Bianco G, Paradiso V, Nuciforo S, Taha-Melitz S, Meier MA, Boldanova T, Pérez-Del-Pulgar S, Rodríguez-Tajes S, von Flüe M, Soysal SD, Kollmar O, Llovet JM, Villanueva A, Terracciano LM, Heim MH, Ng CKY, Piscuoglio S.
PMID: 34863035
Mol Oncol. 2021 Dec 04; doi: 10.1002/1878-0261.13154. Epub 2021 Dec 04.

Hepatocellular carcinomas (HCCs) usually arise from chronic liver disease (CLD). Precancerous cells in chronically inflamed environments may be 'epigenetically primed', sensitising them to oncogenic transformation. We investigated whether epigenetic priming in CLD may affect HCC outcomes by influencing the...

Cite
Gallon J, Coto-Llerena M, Ercan C, et al. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Mol Oncol. 2021;doi: 10.1002/1878-0261.13154.
Gallon, J., Coto-Llerena, M., Ercan, C., Bianco, G., Paradiso, V., Nuciforo, S., Taha-Melitz, S., Meier, M. A., Boldanova, T., Pérez-Del-Pulgar, S., Rodríguez-Tajes, S., von Flüe, M., Soysal, S. D., Kollmar, O., Llovet, J. M., Villanueva, A., Terracciano, L. M., Heim, M. H., Ng, C. K. Y., & Piscuoglio, S. (2021). Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Molecular oncology, . https://doi.org/10.1002/1878-0261.13154
Gallon, John, et al. "Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma." Molecular oncology vol. (2021). doi: https://doi.org/10.1002/1878-0261.13154
Gallon J, Coto-Llerena M, Ercan C, Bianco G, Paradiso V, Nuciforo S, Taha-Melitz S, Meier MA, Boldanova T, Pérez-Del-Pulgar S, Rodríguez-Tajes S, von Flüe M, Soysal SD, Kollmar O, Llovet JM, Villanueva A, Terracciano LM, Heim MH, Ng CKY, Piscuoglio S. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Mol Oncol. 2021 Dec 04; doi: 10.1002/1878-0261.13154. Epub 2021 Dec 04. PMID: 34863035.
Copy Download .nbib Format: NLM
Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension.

PPAR research

Lee DL, Wilson JL, Duan R, Hudson T, El-Marakby A.
PMID: 22190908
PPAR Res. 2011;2011:502631. doi: 10.1155/2011/502631. Epub 2011 Dec 07.

Peroxisome proliferator-activated receptor-alpha (PPAR-α) activation by fenofibrate reduces blood pressure and sodium retention during DOCA-salt hypertension. PPAR-α activation reduces the expression of inflammatory cytokines, such as interleukin-6 (IL-6). Fenofibrate also induces cytochrome P450 4A (CYP4A) and increases 20-hydroxyeicosatetraenoic acid...

Cite
Lee DL, Wilson JL, Duan R, et al. Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension. PPAR Res. 2011;2011:502631doi: 10.1155/2011/502631.
Lee, D. L., Wilson, J. L., Duan, R., Hudson, T., & El-Marakby, A. (2011). Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension. PPAR research, 2011502631. https://doi.org/10.1155/2011/502631
Lee, Dexter L, et al. "Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension." PPAR research vol. 2011 (2011): 502631. doi: https://doi.org/10.1155/2011/502631
Lee DL, Wilson JL, Duan R, Hudson T, El-Marakby A. Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension. PPAR Res. 2011;2011:502631. doi: 10.1155/2011/502631. Epub 2011 Dec 07. PMID: 22190908; PMCID: PMC3236317.
Copy Download .nbib Format: NLM
Interactive Association Between CYP2C9 rs2860905 Polymorphism and Atrial Fibrillation on Ischemic Stroke in Taiwan Biobank Participants.

Pharmacogenomics and personalized medicine

Peng JW, Nfor ON, Ho CC, Hsu SY, Lung CC, Tantoh DM, Chou MC, Liaw YP.
PMID: 34511979
Pharmgenomics Pers Med. 2021 Aug 31;14:1087-1092. doi: 10.2147/PGPM.S310675. eCollection 2021.

PURPOSE: Ischemic stroke accounts for approximately 85% of all strokes. Risk factors include atrial fibrillation, metabolic disorders, and genetic and lifestyle factors. There is limited evidence to support the association between atrial fibrillation and the risk of ischemic stroke...

Cite
Peng JW, Nfor ON, Ho CC, et al. Interactive Association Between CYP2C9 rs2860905 Polymorphism and Atrial Fibrillation on Ischemic Stroke in Taiwan Biobank Participants. Pharmgenomics Pers Med. 2021;14:1087-1092doi: 10.2147/PGPM.S310675.
Peng, J. W., Nfor, O. N., Ho, C. C., Hsu, S. Y., Lung, C. C., Tantoh, D. M., Chou, M. C., & Liaw, Y. P. (2021). Interactive Association Between CYP2C9 rs2860905 Polymorphism and Atrial Fibrillation on Ischemic Stroke in Taiwan Biobank Participants. Pharmacogenomics and personalized medicine, 141087-1092. https://doi.org/10.2147/PGPM.S310675
Peng, Jui-Wen, et al. "Interactive Association Between CYP2C9 rs2860905 Polymorphism and Atrial Fibrillation on Ischemic Stroke in Taiwan Biobank Participants." Pharmacogenomics and personalized medicine vol. 14 (2021): 1087-1092. doi: https://doi.org/10.2147/PGPM.S310675
Peng JW, Nfor ON, Ho CC, Hsu SY, Lung CC, Tantoh DM, Chou MC, Liaw YP. Interactive Association Between CYP2C9 rs2860905 Polymorphism and Atrial Fibrillation on Ischemic Stroke in Taiwan Biobank Participants. Pharmgenomics Pers Med. 2021 Aug 31;14:1087-1092. doi: 10.2147/PGPM.S310675. eCollection 2021. PMID: 34511979; PMCID: PMC8418368.
Copy Download .nbib Format: NLM
Low production of 12α-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70.

Journal of lipid research

Li R, Palmiotti A, de Vries HD, Hovingh MV, Koehorst M, Mulder NL, Zhang Y, Kats K, Bloks VW, Fu J, Verkade HJ, de Boer JF, Kuipers F.
PMID: 34626589
J Lipid Res. 2021;62:100134. doi: 10.1016/j.jlr.2021.100134. Epub 2021 Oct 07.

Bile acids (BAs) play important roles in lipid homeostasis, and BA signaling pathways serve as therapeutic targets for nonalcoholic fatty liver disease (NAFLD). Recently, we generated cytochrome P450, family 2, subfamily C, polypeptide 70 (Cyp2c70

Cite
Li R, Palmiotti A, de Vries HD, et al. Low production of 12α-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70. J Lipid Res. 2021;62:100134doi: 10.1016/j.jlr.2021.100134.
Li, R., Palmiotti, A., de Vries, H. D., Hovingh, M. V., Koehorst, M., Mulder, N. L., Zhang, Y., Kats, K., Bloks, V. W., Fu, J., Verkade, H. J., de Boer, J. F., & Kuipers, F. (2021). Low production of 12α-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70. Journal of lipid research, 62100134. https://doi.org/10.1016/j.jlr.2021.100134
Li, Rumei, et al. "Low production of 12α-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70." Journal of lipid research vol. 62 (2021): 100134. doi: https://doi.org/10.1016/j.jlr.2021.100134
Li R, Palmiotti A, de Vries HD, Hovingh MV, Koehorst M, Mulder NL, Zhang Y, Kats K, Bloks VW, Fu J, Verkade HJ, de Boer JF, Kuipers F. Low production of 12α-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70. J Lipid Res. 2021;62:100134. doi: 10.1016/j.jlr.2021.100134. Epub 2021 Oct 07. PMID: 34626589; PMCID: PMC8596750.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries